Enable JavaScript to visit this website.
Skip directly to content



July 13, 2018 – KIRKLAND, QC – To-date, eight provinces across Canada and the Non-Insured Health Benefits program (NIHB) have added IBRANCETM (palbociclib) to their public drug formularies in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women living with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (mBC).IBRANCE was added to the following public drug benefit formularies per the effective dates indicated below.

IBRANCE is a protein kinase inhibitor that is indicated in combination with an aromatase inhibitor, for the treatment of postmenopausal women with HR-positive, HER2-negative locally advanced breast cancer as initial endocrine-based therapy for their metastatic disease.vi

The addition of IBRANCE to the provincial drug formularies of eight provinces and the NIHB program to-date is consistent with the pan-Canadian Oncology Drug Review (pCODR)’s recommendation for public listing issued on November 21, 2016 and acknowledgement of IBRANCE’s therapeutic value from the Institut national d'excellence en santé et en services sociaux (INESSS)’s scientific committee in Quebec issued on March 15, 2017.viii,ix

About Metastatic Breast Cancer in Canada
mBC is the most advanced stage of breast cancer. It occurs when cancer spreads to other parts of the body such as the lungs, liver, brain or bones.x

Despite improvements made with early detection and treatment, there is currently no cure for mBC and only 22 per cent of patients will survive five years beyond diagnosis.xi,xii

Of the estimated 26,300 Canadian women diagnosed with breast cancer in 2017, about five to 10 per cent received a first diagnosis of metastatic disease.

Approximately 20-30 per cent of women first diagnosed with early stage breast cancer will go on to develop metastatic disease in their lifetime.xvi

About Pfizer Canada
Pfizer Canada is the Canadian operation of Pfizer Inc., one of the world’s leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best-known and most prescribed medicines and vaccines. Historically, Pfizer Inc. has invested more than US $7 billion toward developing safe and effective medicines. At Pfizer, we’re working together for a healthier world. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/PfizerCanada).

For further information:
Corporate Affairs
Pfizer Canada
1-866-9PFIZER (973-4937)



i CADTH. Provincial Funding Summary; Palbociclib (Ibrance) for advanced breast cancer resubmission. May 8, 2018. Available at: https://www.cadth.ca/sites/default/files/pcodr/pcodr_profund_palbociclib... Last accessed May 2018.

ii Régie de l'assurance maladie du Québec (RAMQ). February 1, 2018. Available at: http://www.ramq.gouv.qc.ca/SiteCollectionDocuments/liste_med/liste_med_2... Last accessed May 2018.

iii Pfizer data on file

iv Newfoundland and Labrador Prescription Drug Program. Bulletin No. 76.

v Alberta Health Services. Outpatient cancer drug benefit program. May 8, 2018. Available at: https://www.albertahealthservices.ca/assets/programs/ps-1025651-drug-ben... Last accessed May 2018.

vi IBRANCE Product Monograph. June 5, 2018.

viii Pan-Canadian Oncology Drug Review. Palbociclib (Ibrance) resubmission ABC – pERC final recommendation. November 16,2016. Available at: https://www.cadth.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance... Last accessed May 2018.

ix Institut national d'excellence en santé et en services sociaux (INESSS). For updating lists of medicines. March 15, 2017. Available at: http://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avi... Last accessed May 2018.

x Quebec Breast Cancer Foundation. Metastatic breast cancer. Available at: https://rubanrose.org/breast-cancer/understand/metastatic-breast-cancer. Accessed May 2018.

xi Canadian Breast Cancer Network. Living with metastatic breast cancer. Available at: https://www.cbcn.ca/en/mbc_treatment. Accessed May 2018.

xii Canadian Cancer Society. Survival statistics for breast cancer. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/breast/prognosis-.... Accessed May 2018.

xiii Canadian Cancer Society. Breast cancer statistics. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics.... Accessed May 2018.

xiv Canadian Partnership Against Cancer. Breast cancer control in canada: a system performance special focus report. September 2012. Available at: http://www.systemperformance.ca/report/breast-cancer-control-in-canada-a... May 2018.

xv Canadian Breast Cancer Foundation. Metastatic breast cancer. Available at: http://www.cbcf.org/central/AboutBreastCancerMain/MetastaticBreastCancer.... Accessed May 2018.

xvi Metastatic Breast Cancer Network. 13 facts about metastatic breast cancer. Available at: http://www.mbcn.org/13-facts-about-metastatic-breast-cancer/. Accessed May 2018.